Abstract 6058
Background
Cancer-related fatigue (CRF) is one of the most common side effects and leads to a significant impairment of quality of life (QoL). At the same time many cancer patients suffer from malnutrition. Studies show that both physical activity and a good nutritional status reduce CRF. Until now this has only been considered in isolation. This study aims a comprehensive view to evaluate the relation of fatigue with malnutrition and level of activity.
Methods
18 patients of the oncological sports and exercise therapy at the University Hospital Halle (Saale) were examined in a cross-sectional design. Outcome measures were the relevant values of body composition, such as body mass [% of fat-free mass] (BCM [% of FFM]), extracellular mass to body cell mass (ECM / BCM) and phase angle ϕ, which were determined by bioelectrical impedance analysis (BIA). Moreover CRF with EORTC QLQ FA12, Nutritional related QoL with FAACT, History and Current Level of Activity (Questionnaire from Woll) and Malnutrition with Subjective Global Assessment (SGA). The statistical analysis was made with description and Pearson’s correlations. Following, a linear regression analysis was supplemented with an ANOVA.
Results
The correlation between physical fatigue and habitual physical activity had a correlation coefficient of -0.641 (p = 0.004). Between the physical fatigue and FAACT Total Score a negative linear correlation (correlation coefficient = -0.739, p < 0.01) could be found. The correlation of the physical fatigue and the values from the BIA did not show any significant results. The linear regression analysis showed that 47.8 % of the total fatigue could be explained by the Functional Assessment of Anorexia/Cachexia Therapy (corr. R2 = 0.478, p = 0.001) and that ECM/BCM and BCM [% of FFM] do not provide additional explanatory power.
Conclusions
It could be confirmed that the QoL of cancer patients is strongly limited by the CRF. The negative correlation between habitual activity and physical fatigue supports the hypothesis of the so-called "prehabilitation". It has been shown that it is a legitimate strategy to present nutritional status and level of physical activity in cancer patients with CRF at the same time.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
P. Jahn: Research grant / Funding (institution): Chugai. C. Leithold: Honoraria (self): Fresenius. All other authors have declared no conflicts of interest.
Resources from the same session
5105 - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: association with toxicity and treatment outcome
Presenter: Aude DESNOYER
Session: Poster Display session 3
Resources:
Abstract
1877 - Advanced clear-cell renal cell carcinoma (accRCC): association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome.
Presenter: Annelies Verbiest
Session: Poster Display session 3
Resources:
Abstract
5543 - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Presenter: Valerio Iebba
Session: Poster Display session 3
Resources:
Abstract
2689 - mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors
Presenter: Cristina Suarez Rodriguez
Session: Poster Display session 3
Resources:
Abstract
3069 - Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in Advanced Renal Cell Carcinoma (RCC)
Presenter: Aly-Khan Lalani
Session: Poster Display session 3
Resources:
Abstract
5089 - Finding the Right Biomarker for Renal Cell Carcinoma (RCC): Nivolumab treatment induces the expression of specific peripheral lymphocyte microRNAs in patients with durable and complete response.
Presenter: Lorena Incorvaia
Session: Poster Display session 3
Resources:
Abstract
2594 - Algorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)
Presenter: In Hwa Um
Session: Poster Display session 3
Resources:
Abstract
2566 - High baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma
Presenter: Aska Drljevic-nielsen
Session: Poster Display session 3
Resources:
Abstract
2675 - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
Presenter: Daniel George
Session: Poster Display session 3
Resources:
Abstract
1541 - TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Presenter: Bozo Kruslin
Session: Poster Display session 3
Resources:
Abstract